News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
69,514 Results
Type
Article (1918)
Company Profile (2)
Press Release (67594)
Section
Business (21468)
Career Advice (9)
Deals (4552)
Drug Development (8185)
FDA (1815)
Job Trends (805)
News (37068)
Policy (3568)
Tag
Academia (92)
Alliances (8124)
Alzheimer's disease (121)
Antibody-drug conjugate (ADC) (10)
Approvals (1835)
Artificial intelligence (12)
Bankruptcy (8)
Best Places to Work (591)
Biosimilars (15)
Breast cancer (15)
Cancer (168)
Career advice (9)
Cell therapy (18)
Clinical research (6976)
Collaboration (68)
COVID-19 (182)
C-suite (9)
Data (146)
Diabetes (11)
Diagnostics (595)
Drug discovery (12)
Duchenne muscular dystrophy (7)
Earnings (7526)
Events (6923)
Executive appointments (40)
FDA (1921)
Funding (45)
Gene therapy (14)
GLP-1 (40)
Government (235)
Healthcare (1076)
Infectious disease (187)
Inflammatory bowel disease (15)
Intellectual property (8)
IPO (1618)
Job creations (240)
Job search strategy (9)
Layoffs (6)
Legal (948)
Liver cancer (15)
Lung cancer (27)
Lymphoma (10)
Manufacturing (25)
Medical device (1114)
Medtech (1115)
Mergers & acquisitions (3005)
Metabolic disorders (33)
Neuroscience (155)
NextGen: Class of 2025 (219)
Non-profit (61)
Northern California (115)
Obesity (15)
Ovarian cancer (7)
Parkinson's disease (12)
Patents (13)
People (4939)
Phase I (1889)
Phase II (2909)
Phase III (2651)
Pipeline (66)
Postmarket research (251)
Preclinical (653)
Radiopharmaceuticals (22)
Rare diseases (22)
Real estate (598)
Regulatory (2568)
Research institute (91)
Schizophrenia (6)
Series A (11)
Southern California (112)
Startups (421)
United States (1027)
Vaccines (20)
Date
Last 7 days (39)
Last 30 days (176)
Last 365 days (3165)
2025 (334)
2024 (3266)
2023 (3822)
2022 (7017)
2021 (6377)
2020 (5872)
2019 (3871)
2018 (3014)
2017 (3571)
2016 (3180)
2015 (4043)
2014 (3038)
2013 (2601)
2012 (2776)
2011 (2904)
2010 (2663)
Location
Africa (79)
Arizona (7)
Asia (21251)
Australia (2425)
California (264)
Canada (195)
China (124)
Connecticut (12)
Europe (12344)
Florida (15)
Illinois (16)
India (8)
Indiana (12)
Japan (58)
Maryland (66)
Massachusetts (185)
Minnesota (25)
New Jersey (147)
New York (118)
North Carolina (53)
Northern California (115)
Pennsylvania (38)
South America (105)
Southern California (112)
Texas (18)
Utah (10)
Virginia (15)
69,514 Results for "neuraxis ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025
·
3 min read
Press Releases
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
January 21, 2025
·
3 min read
BioMidwest
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) today announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy.
March 27, 2024
·
5 min read
Business
NeurAxis Reports First Quarter 2024 Financial Results
NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, announced results for the first quarter 2024 for the period ended March 31, 2024.
May 22, 2024
·
12 min read
Business
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.
April 9, 2024
·
13 min read
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
NeurAxis, Inc. will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 21, 2024
·
1 min read
Business
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) will report summarized financial results for its first quarter 2024, for the period ended March 31, 2024, on Wednesday, May 22, 2024, before market open.
May 15, 2024
·
3 min read
Press Releases
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
January 8, 2025
·
4 min read
Press Releases
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
December 11, 2024
·
4 min read
Business
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024.
January 31, 2024
·
4 min read
1 of 6,952
Next
